Healthcare & Pharmaceutical Market Research in India

BioNixus is a healthcare market research company serving India, delivering ethics-committee-compliant HCP surveys, KOL mapping, and patient research aligned with CDSCO, ICMR, and the New Drugs and Clinical Trials Rules 2019. BioNixus combines primary research depth with physician access spanning public government hospitals and private healthcare systems, across Tier-1, Tier-2, and Tier-3 cities and multiple regional languages.

A healthcare market research company in India designs and executes studies covering physician prescribing behaviour, public and private payer dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, diagnostics, and medical device companies launching or scaling in the Indian market.

India's healthcare system combines a rapidly expanding public insurance layer — anchored by Ayushman Bharat / PM-JAY, one of the world's largest government-funded health insurance schemes — with state-level schemes and a fast-growing private insurance and hospital sector. Regulatory oversight sits with CDSCO under the Drugs Controller General of India (DCGI) and the Ministry of Health and Family Welfare, while clinical research is governed by ICMR guidelines and the New Drugs and Clinical Trials Rules 2019. Fieldwork must also account for 22 official languages, a sharp urban-rural divide, and distinct Tier-1, Tier-2, and Tier-3 city dynamics.

BioNixus covers diabetes and metabolic disease (India has one of the largest diabetic populations in the world), cardiovascular disease, oncology, infectious disease, digital health and telemedicine, maternal and child health, medical devices and diagnostics, neurology and psychiatry, and consumer health across the Indian market.

Yes. BioNixus maintains physician and specialist access spanning India's leading research and referral centres, including AIIMS (New Delhi and the newer AIIMS campuses across states), Tata Memorial Hospital for oncology, PGIMER Chandigarh, CMC Vellore, and NIMHANS Bangalore for neuroscience and psychiatry. Recruitment spans both government (public) hospital physicians and private-sector specialists, with multilingual fieldwork support.

Focused HCP surveys typically complete in 3–4 weeks. Full mixed-method programmes including patient research across multiple states, languages, and payer-type segments (public scheme beneficiaries versus private-pay patients) typically run 6–10 weeks depending on therapy area, ethics committee review timelines, and respondent scarcity in specialist fields.

Yes. BioNixus designs and executes Indian patient and HCP research in line with the Digital Personal Data Protection Act 2023 (DPDP Act) and Institutional Ethics Committee (IEC) requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with Indian data protection standards.

Yes. Indian research modules can run alongside comparable cells in the USA, UK, EU5, GCC markets (Saudi Arabia, UAE), and other Asia-Pacific markets — using consistent instruments so global portfolio committees can benchmark India against other priority markets from a single research partner.